Related Experiment Videos
Signal generation in a non-EU country
K Hartmann1, C Ciorciaro, M Kuhn
1Swiss Drug Monitoring Center SANZ, Neubruchstrasse 37, CH-7000 Chur, Switzerland.
Pharmacoepidemiology and Drug Safety
|April 10, 2004
Summary
Early detection of adverse drug reactions (ADRs) is crucial. A Swiss system identified 114 drug-related, unlabelled ADRs, leading to labeling changes and improving patient safety.
Area of Science:
- Pharmacovigilance
- Drug Safety
- Regulatory Science
Background:
- Post-marketing surveillance aims to detect serious, unknown adverse events.
- Spontaneous adverse event reports have variable signal-generating value.
- The Swiss Drug Monitoring Center SANZ implemented an early signal detection system in 1991.
Purpose of the Study:
- To describe the implementation and performance of a computer-assisted early signal detection system for adverse drug reactions (ADRs).
- To assess the system's ability to identify new, rare, serious, and quality of life affecting ADRs.
Main Methods:
- A computer system screened individual case reports using predefined criteria to identify potential signals.
- Potential signals were further processed to quantify their signal-generating value.
- Drug-related, unlabelled, and serious adverse events were specifically analyzed.
Main Results:
- Out of 2072 (53%) potential signals identified, 27% (565) were drug-related and unlabelled.
- 8% (173) of these signals were also classified as serious.
- 114 labelling changes were made based on the detected ADRs.
Conclusions:
- The computer-assisted early signal generation model effectively detects new, rare, serious, and quality of life affecting ADRs in a small population.
- This system contributes significantly to drug safety and regulatory actions.
- Detected ADRs require careful interpretation considering the limitations of spontaneous reporting, precluding pharmacoepidemiologic conclusions.